New Diagnostic to Rapidly Distinguish Infection from Tuberculosis

A group of scientists have developed a potential new experimental diagnostic test that is able to quickly distinguish individuals with active tuberculosis (TB) from those with latent TB infection.

If the preliminary results of the study will be confirmed in a larger population sample, the new diagnostic system could allow more effective strategies to control the spread of the re-emerging pathology.

Tuberculosis - Spread - Symptoms - Diagnosis - Treatment - FAQs
Tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lung. It may spread to other organs.

The work was performed by a group of scientists from the Catholic University of Rome, the National Institute of Infectious Diseases "L. Spallanzani" of Rome.

TB is an infection caused by Mycobacterium tuberculosis, the bacterium known as Koch's bacillus, named after its discoverer (Robert Koch) in 1882. Following infection with the bacillus, two different scenario may occur: "active disease", clinically evident, and that - if not properly treated - can lead to death and the so called "latent infection", that is asymptomatic and that can last for a lifetime.

"The tuberculin skin test- explains Delia Goletti, corresponding author of the paper - has several drawbacks, primarily that is unable to differentiate between infection with environmental mycobacteria (typically not dangerous to humans), vaccination with Bacillus of Calmette et Guerin (BCG) and infection with M. tuberculosis. A new assay is being used since ten years, which includes a blood test, based on specific proteins of Mycobacterium tuberculosis. The new blood test, called "Interferon-? release assays (IGRA)", based on the release of interferon-? in response to M. tuberculosis-specific antigens, is able to selectively identify those who have contracted TB infection.

Drug Resistance – Antibiotic or Antimicrobial Resistance
Drug resistance is often a problem in malaria, tuberculosis, HIV, sexually transmitted diseases and hospital acquired diseases. Judicious use of antibiotics can control the problem.

"However - continues Goletti - IGRA, as well as the tuberculin test, are not able to distinguish people with latent TB infection compared to those with active TB disease ".

"The results of our study", said Giovanni Delogu, first author of the article, - demonstrate that it is possible to distinguish those infected from those with the disease, by simply performing an extra blood test using a protein of the bacillus named HBHA".

US Misses Goal to Eradicate Tuberculosis by 2010
The United States last year saw a sizable drop in the number of tuberculosis cases, but missed its goal of eradicating the disease by 2010, US health officials said Thursday.

"In order for the test to be effective, the HBHA protein must have special features, and to date it has been difficult to obtain large amounts of this protein. - continued Delogu -. Well, our research group has developed an innovative experimental protocol to obtain large amounts of protein with limited costs, opening the possibility to use this test on a large scale ".

"In this study we have developed an innovative diagnostic algorithm, which consists of a response to the protein HBHA in combination with the IGRA and the results have shown that the response to HBHA associates with latent TB infection. This procedure allows to rapidly identify those who really need the treatment for active TB ", concluded Goletti.

National Tuberculosis Control Program (NTCP) is All Set to be Revised
For the past 3 consecutive years, the Government has been successful in achieving the global objectives of 70% new case detection and 85% treatment success rate and so NTCP will be revised.

"The response to HBHA can be used as a biomarkers for latent TB infection and then to some extent can be considered as a response of protection to TB. It is important to understand what are the mechanisms triggered by the infection which can cause the appearance or not of the disease", said Stefania Zanetti, professor of Microbiology at the University of Sassari.

"These results - concludes the researchers - open the road to a multicenter study-"In the future we plan to extend the study to a larger number of patients, giving priority to certain groups where diagnosing active TB can be challenging, such as immunocompromised individuals and children. We also plan to tests the new assay in countries with a high burden of TB".

The study has been published on the international journal PLoS One.

Source-ANI